Journal List > Tuberc Respir Dis > v.71(4) > 1001660

TOOLS
Kim: Clinical Year in Review of Venous Thromboembolism
Review
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2011; 71(4): 245-248.

Published online: 31 October 2011

DOI: https://doi.org/10.4046/trd.2011.71.4.245

Clinical Year in Review of Venous Thromboembolism

Yang-Ki Kim, M.D., Ph.D.

Division of Respiratory and Allergy Medicine, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

Address for correspondence: Yang-Ki Kim, M.D., Ph.D. Division of Respiratory and Allergy Medicine, Department of Internal Medicine, Soonchunhyang University Hospital, 22, Daesagwan-gil, Yongsan-gu, Seoul 140-743, Korea. Phone: 82-2-709-9427, Fax: 82-2-709-9083, kyklung@schmc.ac.kr

Received 23 May 2011       Accepted 23 May 2011

Copyright © 2011. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Abstract

Venous thromboembolism represents as an obstruction of a vein by a blood clot in the blood stream. The most common manifestations of venous thromboembolism (VTE) are pulmonary embolism and deep vein thrombosis (DVT) of the lower extremity. This article reviews the recent advances in this spectrum and introduces new drugs that will be used in venous thromboembolism in the near future.

Keywords: Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis

References

1. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011. 9:85–91.
2. Sweetland S, Green J, Liu B, Berrington de González A, Canonico M, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009. 339:b4583.
3. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost. 2010. 8:101–106.
4. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008. 133:6 Suppl. 454S–545S.
5. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993. 69:236–239.
6. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010. 153:523–531.
7. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006. 355:1780–1789.
8. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008. 149:481–490. W94
9. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009. 361:2342–2352.
10. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010. 363:2499–2510.
TOOLS
Similar articles